Epitalon is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — derived from the natural polypeptide Epithalamin, a thymus-and-pineal gland extract first isolated by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the early 1980s. Where Epithalamin is a crude extract, Epitalon is the purified four-amino-acid sequence that Khavinson's group identified as the biologically active core. The research programme that followed is among the most sustained investigations into a single peptide compound in the published gerontology literature.
Key Takeaways
- —Epitalon is a 4-amino-acid synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from natural Epithalamin, developed by the Khavinson Institute in St. Petersburg.
- —A 15-year cohort study in older adults (Khavinson et al., 2003) showed a 1.6–1.8× reduction in mortality in those receiving Epithalamin or Epitalon treatment cycles versus untreated controls.
- —Epitalon activates telomerase (hTERT expression) in somatic cells — extending telomere length in cultured human fetal fibroblasts across up to 44 additional population doublings (Khavinson et al., Bull Exp Biol Med, 2003).
- —Current regulatory status: not FDA-approved; available as research-grade peptide and, in some countries, as a compounded formulation.
Epitalon is the short synthetic version of Epithalamin, a bioregulatory peptide fraction secreted by the pineal gland and thymus. Khavinson's foundational hypothesis — developed over decades of experimental and clinical work — is that the pineal gland produces short peptides that regulate gene expression patterns associated with aging, and that supplying these peptides exogenously can partially restore youthful transcriptional profiles in aged tissue.
The tetrapeptide sequence Ala-Glu-Asp-Gly was identified as the minimal active unit. It is water-soluble, small enough for direct tissue penetration, and stable under standard peptide storage conditions. Molecular weight is approximately 390 Da — making it one of the smallest bioactive peptides in active research.
The "peptide bioregulation" theory Khavinson developed differs meaningfully from conventional pharmacology. Rather than targeting a single receptor, Epitalon appears to function as a transcriptional regulator — binding to chromatin directly and modulating gene expression at the epigenetic level. This is not a conventional receptor-agonist model. Published chromatin interaction data from the Khavinson group shows Epitalon directly interacting with the gene promoter regions of antioxidant enzymes, melatonin synthesis genes, and telomerase reverse transcriptase.
Three mechanisms have the strongest published evidence basis:
Telomerase activation (hTERT upregulation): The most-cited finding in the Epitalon literature. Khavinson et al. (2003) demonstrated that Epitalon increased telomerase activity and hTERT expression in cultured human fetal fibroblasts, allowing the cell line to undergo 44 additional population doublings beyond the Hayflick limit compared to untreated controls. Telomere length was maintained and in some conditions extended.
Melatonin regulation: Epitalon increases melatonin synthesis and secretion from the pineal gland, particularly in aged animals where pineal melatonin production has declined. This is relevant not only for circadian rhythm entrainment but also for the downstream antioxidant and anti-inflammatory effects of melatonin itself.
Antioxidant enzyme expression: Consistent data across rat, mouse, and in-vitro models shows Epitalon upregulating superoxide dismutase (SOD), catalase, and glutathione peroxidase. Oxidative damage markers (lipid peroxidation, protein carbonylation) are reduced in treated animals.
Epitalon (Ala-Glu-Asp-Gly) increased telomerase activity and extended the replicative lifespan of human fetal fibroblasts by up to 44 additional population doublings beyond Hayflick's limit in published cell culture experiments (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003). The mechanism involves upregulation of hTERT — the catalytic subunit of telomerase — at the transcriptional level, making Epitalon one of only a handful of compounds with published telomerase-activating data in human cells.
The most significant clinical data comes from a 15-year longitudinal cohort study conducted at the Geriatric Centre in St. Petersburg (Khavinson & Morozov, 2003). Patients aged 60–74 received either Epithalamin peptide extract, Thymalin (another thymic peptide), or no treatment, with follow-up over 15 years. Key findings:
A limitation is significant: these were not randomised controlled trials in the Western regulatory sense. Allocation was not randomised, and confounders were not fully controlled. The Khavinson group's work has been published primarily in Russian journals and PMC translations, with limited independent replication by Western research groups. This must be stated clearly when evaluating the evidence quality.
The 48% vs 72% survival difference over 15 years is striking if taken at face value. The appropriate caveat is the study design: these results come from an observational cohort, not a randomised trial. Independent replication in a prospective RCT has not been published. The data should be read as hypothesis-generating rather than confirmatory.
Published clinical protocols and the compounding literature converge on the following framework:
| Parameter | Range | Notes |
|---|---|---|
| Dose per injection | 5–10 mg | Khavinson clinical protocols used 10 mg/day |
| Route | Subcutaneous or intramuscular | Both routes used in published work |
| Cycle duration | 10–20 days | Most commonly 10 days |
| Frequency | 1–2 cycles per year | Some longevity protocols use spring and autumn cycles |
| Reconstitution | Bacteriostatic water | Standard 1–2 mL per 10 mg vial |
Example cycle: 10 mg SC injection daily for 10 days, repeated once or twice per year. Some practitioners use 5 mg for the initial cycle to assess tolerability.
The "peptide bioregulation" literature from the Khavinson group typically used intramuscular injection, but subcutaneous administration is more practical and has comparable bioavailability for a peptide this small.
Across all published Khavinson group studies and the broader animal research literature, no serious adverse events have been attributed to Epitalon or Epithalamin. The compounds appear to be well-tolerated at clinical doses in both animal models and human cohorts. Injection site reactions (transient local erythema) are the most commonly noted event.
In Khavinson's published clinical work spanning over two decades and multiple cohort studies, neither Epitalon (tetrapeptide) nor its parent compound Epithalamin have been associated with serious adverse events. The safety data should be contextualised: trials were conducted primarily in St. Petersburg under protocols not fully equivalent to Western GCP standards, and independent third-party safety surveillance data is limited.
The absence of a randomised controlled trial in Western regulatory conditions means Epitalon lacks the safety database that FDA-reviewed compounds carry. This is a meaningful evidence gap, not evidence of safety. Researchers considering Epitalon protocols should treat the existing literature as preliminary until independently replicated.
Before sourcing Epitalon, the Next Pep peptide library provides the full profile — Ala-Glu-Asp-Gly tetrapeptide structure, telomerase/hTERT activation mechanism, the Khavinson cohort data, and the lack of Western RCT validation — all cross-referenced against published literature. That context is critical when evaluating vendor claims that dramatically overstate what the evidence shows.
Use the comparison tool to put Epitalon alongside other longevity-focused peptides — comparing mechanisms, evidence quality, and access routes. If you're running any injectable protocol, the dosing calculator handles reconstitution maths: vial mg to draw volume and syringe units.
No. Epithalamin is a crude polypeptide extract isolated from the pineal gland and thymus. Epitalon (Ala-Glu-Asp-Gly) is the purified synthetic tetrapeptide that Khavinson's group identified as the active core sequence within Epithalamin. Epitalon is more reproducible, easier to synthesise, and is the compound used in most modern research protocols. Some older Khavinson studies used Epithalamin; newer work uses Epitalon.
Published cell culture data from Khavinson et al. (2003) shows that Epitalon increased telomerase activity and allowed human fetal fibroblasts to divide approximately 44 times more than untreated controls before reaching replicative senescence. This is not the same as demonstrating telomere lengthening in vivo in a healthy adult human — those data don't exist yet. The cell culture findings are genuine but should not be over-extrapolated.
Most published Khavinson protocols use 10-day cycles of 5–10 mg daily, repeated 1–2 times per year (typically spring and autumn). The rationale for spacing cycles is to allow natural regulatory reset and avoid receptor desensitisation, though there is no formal receptor downregulation data specific to Epitalon.
Some practitioners use intranasal Epitalon, but the published clinical and preclinical data is based almost entirely on subcutaneous or intramuscular administration. Intranasal bioavailability data for Epitalon specifically has not been published. Given the compound's small size (390 Da), nasal absorption is plausible but unquantified.
The mechanisms are distinct. GHK-Cu is an endogenous tripeptide that modulates copper-dependent enzymes, MMP activity, and collagen synthesis — its primary effects are on connective tissue remodelling and gene expression patterns related to tissue repair. Epitalon's primary action is at the telomerase/chromatin level with documented pineal–melatonin axis effects. Both are "epigenetic modulators" in a broad sense, but they target different biological processes and are often combined in longevity protocols precisely because their mechanisms don't overlap.
This article is for research and educational purposes only. Epitalon is not FDA-approved for any therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.